Sobrevida de los pacientes con Cáncer de próstata en tratamiento hormonal con acetato de leuprolide y bicalutamida en Hospital Solca de Guayaquil en el periodo 2018-2022.

Abstract

Introduction: Prostatic cancer is a common type of cancer in men, In Ecuador it’s ranked tenth among the most common neoplasms with a high mortality rate. Among the hormonal therapy, leuprolide acetate is a GnRH analogue and Bicalutamide is a first generation non-steroidal anti androgenic, both are part of the hormonal treatment regimen currently used in Guayaquil city Methodology: A cross-sectional, retrospective, observational, analytical study of 99 patients who met the inclusion criteria throughout the inspection of medical records during the period 2018-2022 in Hospital Solca of Guayaquil city Results: From 99 patients included in this study, 64 of them had a survival rate of 5 years which represents 69.57%, 28 patients died corresponding to the 30.43%. According to the cancer stage, we observed that those patients in T2 stage with hormonal treatment presented a higher survival rate representing 70.59% in its group. According to the admission PSA levels, the 10 - 50 ng/dl range presented a higher survival rate percentage of 70.18%. Conclusion: It is concluded that the survival during the 5-year period of patients with prostate cancer undergoing hormonal treatment with leuprolide acetate and bicalutamide at the Solca Hospital in Guayaquil corresponds to 69.57% of the patients based on our sample of 99 diagnosed patients in 2018.